Skip to main content
. Author manuscript; available in PMC: 2020 Sep 10.
Published in final edited form as: Vaccine. 2019 Mar 18;37(38):5745–5753. doi: 10.1016/j.vaccine.2019.02.058

Fig. 1.

Fig. 1.

Epidemiology and economics research priorities, Measles & Rubella Initiative web-based survey, 2016 (n = 157). Note: Other epidemiology and economics research questions that were selected by fewer respondents as a priority: What are the best methods to estimate the threshold population size and susceptible density required to sustain measles and/or rubella virus transmission in various settings? (11%); What is the economic burden of measles outbreaks in low- and middle-income countries? (11%); What are the best methods for measuring disease burden of measles and rubella? (8%); What is the epidemiology of rubella/CRS in developing countries with different birth rates? (8%); What is the prevalence of measles virus susceptibility among human immunodeficiency virus (HIV)-infected adults in high HIV-prevalence settings and does this depend on coverage of highly active antiretroviral therapy (HAART)? (4%); What is the economic burden of CRS at global, regional and national levels? Does the economic burden differ for low- and middle-income countries? (3%).